113 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Nivolumab in Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Nivolumab;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Solu-medrol;   Drug: Dexamethasone
2 Recruiting Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Subjects With Advanced Liver Cancer
Condition: Hepatocellular Carcinoma
Interventions: Biological: Nivolumab;   Drug: Sorafenib;   Drug: Ipilimumab
3 Not yet recruiting Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Oligometastatic Melanoma
Interventions: Drug: Nivolumab 1mg/kg;   Drug: Ipilimumab;   Drug: Nivolumab 3 mg/kg
4 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
5 Not yet recruiting Nivolumab With DC Vaccines for Recurrent Brain Tumors
Conditions: Malignant Glioma;   Astrocytoma;   Glioblastoma
Interventions: Drug: nivolumab;   Biological: DC
6 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
7 Recruiting A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: 5-azacytidine;   Drug: Nivolumab;   Behavioral: Phone Call
8 Recruiting Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: nab-Paclitaxel;   Drug: Nivolumab;   Drug: Gemcitabine;   Drug: Carboplatin
9 Recruiting Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Conditions: Melanoma;   Uveal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
10 Recruiting Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: 5-azacitidine
11 Recruiting Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Conditions: Childhood Solid Neoplasm;   Metastatic Melanoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
12 Recruiting Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab
13 Recruiting Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Temozolomide
14 Recruiting Neoadjuvant Nivolumab in Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: Nivolumab
15 Not yet recruiting Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Condition: Leukemia
Interventions: Drug: Lirilumab;   Drug: Nivolumab;   Drug: Azacitidine
16 Recruiting Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse
Conditions: Leukemia;   Acute Myeloid Leukemia
Intervention: Drug: Nivolumab
17 Recruiting Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers
Conditions: Non-Small Cell Lung Cancer;   Melanoma;   Head and Neck Squamous Cell Cancer;   Pancreatic Cancer;   Colorectal Cancer;   Glioblastoma Multiforme
Interventions: Drug: FPA008;   Drug: Nivolumab
18 Recruiting Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
Condition: Malignant Melanoma
Interventions: Drug: Nivolumab + Placebo;   Drug: Nivolumab + Ipilimumab;   Drug: Double Placebo Control
19 Recruiting A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Condition: Brain Metastases
Interventions: Drug: Fotemustine;   Drug: Fotemustine and Ipilimumab;   Drug: Ipilimumab and nivolumab
20 Recruiting Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Conditions: Adult Solid Neoplasm;   Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years